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Introduction {#ijc32365-sec-0001}
============

Colorectal cancer (CRC) and type 2 diabetes mellitus (T2DM) are multifactorial diseases that have several risk factors in common (e.g., high BMI, physical inactivity) and both have shown an increase in incident rates over the past decades.[1](#ijc32365-bib-0001){ref-type="ref"}, [2](#ijc32365-bib-0002){ref-type="ref"} T2DM has been associated with an increased CRC risk (20--40%).[3](#ijc32365-bib-0003){ref-type="ref"} An interesting hypothesis underlying this association involves the insulin‐like growth factor (IGF) pathway. In this hypothesis, chronic hyperinsulinemia in T2DM patients leads to increased IGF levels, which can accelerate the progression from adenoma to cancer.[4](#ijc32365-bib-0004){ref-type="ref"} Previous research within the Netherlands Cohort Study (NLCS) studied single nucleotide polymorphisms (SNPs) in the IGF pathway in relation to CRC risk and found that carrying more risk alleles was associated with an increased CRC risk in men, specifically an increased proximal and distal colon cancer risk but not rectal cancer risk.[5](#ijc32365-bib-0005){ref-type="ref"} T2DM was associated with an increased proximal colon cancer risk in women in previously published data within the NLCS[6](#ijc32365-bib-0006){ref-type="ref"} and this confirmed findings from other cohort studies.[7](#ijc32365-bib-0007){ref-type="ref"} Here, we aimed to investigate whether carrying unfavorable alleles in the IGF pathway further increased the CRC risk associated with diabetes. Genetic variants were used as markers of pathway involvement. Finding a further increased CRC risk in diabetics with unfavorable alleles in the IGF pathway would substantiate the hypothesis that diabetes or chronic hyperinsulinemia increases CRC risk by influencing the IGF pathway.

Materials and Methods {#ijc32365-sec-0002}
=====================

Study population and design {#ijc32365-sec-0003}
---------------------------

The NLCS includes 120,852 men and women from the Dutch population, who were 55--69 years old at baseline in 1986 when completing a self‐administered questionnaire on diet and cancer.[8](#ijc32365-bib-0008){ref-type="ref"} Roughly 90,000 participants also provided toenail clippings when returning the baseline questionnaire. Toenail DNA is a valid DNA source for genotyping.[9](#ijc32365-bib-0009){ref-type="ref"} For reasons of efficiency, DNA isolation, the processing of questionnaires and follow‐up, the NLCS is characterized by a case--cohort approach. This approach entails that a random subcohort of 5,000 individuals, selected at random immediately after baseline, is followed‐up for vital status to estimate the accumulated person‐time at risk by record linkage to the municipal registries (\>99% complete). The whole cohort is followed‐up for incident cancer by record linkage to the Dutch cancer registry and the national pathology database (PALGA)[10](#ijc32365-bib-0010){ref-type="ref"} (\>96% complete).[11](#ijc32365-bib-0011){ref-type="ref"} Baseline exclusion of participants with a history of cancer (except skin cancer) left 4,774 subcohort members. After 16.3 years, there were 3,441 incident CRC cases (ICD‐O 153--154). Toenail clippings were available for 3,768 of 4,774 subcohort members (78.9%) and 2,580 of 3,441 CRC cases (75.0%). Finally, after exclusion of missing inconsistent / incomplete questionnaires and missing data on diabetes and covariates, 1907 CRC cases, 565 proximal colon cancer cases (ICD‐O 153.0, 153.1, 153.4, 153.5 and 153.6), 533 distal colon cancer cases (codes 153.2, 153.3 and 153.7) and 432 rectal cancer cases (code 154.1) were available for analyses with respect to the genetic risk score (GRS).

Assessment of T2DM status {#ijc32365-sec-0004}
-------------------------

T2DM status was derived from the baseline questionnaire based on the question: "Has a physician ever diagnosed you with diabetes mellitus and what was your age at that time?" Individuals who reported to have been diagnosed with DM at age 30 years or older were classified as T2DM. This cut‐off point was based on epidemiological data on DM prevalence and previous literature.[12](#ijc32365-bib-0012){ref-type="ref"} Individuals with a diagnosis of DM before the age of 30 years were regarded as non‐T2DM in our study.

Variant selection, genotyping, the GRS and the *IGF1* 19‐CA repeat {#ijc32365-sec-0005}
------------------------------------------------------------------

We selected SNPs in genes encoding for factors in or regulatory to the IGF pathway and genes encoding for adiponectin, adiponectin receptors and peroxisome proliferator‐activated receptor gamma, as these hormones regulate insulin resistance. Briefly, SNPs were selected through literature and had to be associated with CRC or other obesity‐related cancers (e.g., breast cancer), T2DM risk or related traits (e.g., body size or markers of insulin resistance). A full description of our gene and SNP selection strategy, including a list of the selected SNP variants and references to the literature on which selection is based, is available in the paper and Supplemental Material of Simons *et al*.[5](#ijc32365-bib-0005){ref-type="ref"} A total of 24 SNPs were successfully genotyped on the SEQUENOM® MassARRAY® system (Hamburg, Germany; now known as Agena Bioscience, Hamburg, Germany) and an *IGF1* 19‐CA repeat polymorphism was genotyped by PCR amplification and subsequent analysis of the PCR products' length using the 96‐capillary ABI 3730xl DNA Analyzer. SNP genotypes were reproducible in 98.8% of 314 random duplicate samples. SNP call rates were 92.6% or higher, with one exception of 83.6% (rs4773082). Twenty‐three out of 24 SNPs adhered to Hardy--Weinberg equilibrium (HWE). We did not exclude the SNP that deviated from HWE (rs1342387) because one in 20 tests may be expected to be significant by chance alone. We only used samples with a sample call rate of \>95% in statistical analyses, which led to the exclusion of 532 samples. We aggregated 18 SNPs into a GRS, as for these SNPs, the risk allele in relation to the endpoints mentioned above was unequivocal on the basis of previous studies. Which allele (minor or major allele) was the risk allele can be found in the Supplemental Material of Simons *et al*.[5](#ijc32365-bib-0005){ref-type="ref"} Per SNP, individuals carry 2 (homozygotes for the risk allele), 1 (heterozygotes) or 0 (homozygotes for the other allele) risk alleles. The number of risk alleles carried by an individual was summed for the 18 SNPs. The theoretical range of a GRS based on 18 SNPs is between 0 and 36 risk alleles. The GRS was categorized into tertiles based on the distribution in the subcohort. The *IGF1* 19‐CA repeat polymorphism had a call rate of 70.7% and was reproducible in 93.6% of 314 duplicate samples. This variant was analyzed separately from the GRS, as the direction of the association with CRC remains uncertain and because it is a conceptually different variant (not a single base pair change, but a variation in the number of CA repeats). According to Rosen *et al*.,[13](#ijc32365-bib-0013){ref-type="ref"} we distinguished between individuals homozygous for the wild‐type allele (192/192 CA repeats), heterozygous individuals (192/non‐192 CA repeats), and individuals carrying two variant alleles (non‐192/non‐192 CA repeats).

Statistical analysis {#ijc32365-sec-0006}
--------------------

Hazard ratios (HRs) and 95% confidence intervals (CIs) for CRC overall, by sex (only CRC), and by subsite were estimated using Cox proportional hazards regression analysis for combined categories of T2DM status with tertiles of the GRS and categories of the *IGF1* 19‐CA repeat polymorphism. To adjust for the additional variance introduced from sampling the subcohort from the total cohort, standard errors were estimated using the robust Huber--White sandwich estimator.[14](#ijc32365-bib-0014){ref-type="ref"} Exclusion of participants with inconsistent/incomplete baseline questionnaires left 2,729 subcohort members and 1,821 CRC cases which could be categorized in one of the tertiles of the GRS, and 2,042 subcohort members and 1,657 CRC cases with *IGF1* 19‐CA repeat status available for analyses. Models were adjusted for potential confounders \[age (years), body mass index (BMI, kg/m^2^), pant/skirt size as a proxy for abdominal circumference[15](#ijc32365-bib-0015){ref-type="ref"} (below, or equal to or above median size), first‐degree family history of CRC (yes/no), smoking status (never, ex, current), alcohol intake (0, 0.1--29, ≥30 g/day), intake in g/day of total meat, vegetables, fish, sweets, added sugar, saturated fats and fiber, total energy intake (kcal/day), and nonoccupational physical activity (≤30, \>30, \>60, \>90 min/day)\]. The relative excess risk due to interaction (RERI) was calculated according to Rothman *et al*.,[16](#ijc32365-bib-0016){ref-type="ref"} though we conservatively refrained from doing so in analyses including the *IGF1* 19‐CA repeat polymorphism, as the combined category at lowest risk was not clear. Corresponding 95% bias‐corrected confidence intervals for the RERI were estimated by bootstrapping (n bootstrap samples = 1,000).[17](#ijc32365-bib-0017){ref-type="ref"} Multiplicative interactions were assessed using the Wald test. All analyses were conducted using Stata version 12 (Stata Corp., College Station, TX). Statistical significance was indicated by a *p*‐value \<0.05 for two‐sided testing.

Results {#ijc32365-sec-0007}
=======

Table [1](#ijc32365-tbl-0001){ref-type="table"} shows the distribution of subcohort members with and without T2DM across categories of age, sex, the GRS, the *IGF1* 19‐CA repeat polymorphism and potential confounders. Compared to subcohort members without T2DM, subcohort members with T2DM were older (*p* \< 0.001) and had a significantly lower intake of sweets and added sugar (*p* \< 0.001 for both).

###### 

Baseline characteristics of subcohort members and CRC cases with and without type 2 diabetes mellitus in the Netherlands Cohort Study

                                                                          Subcohort members   CRC Cases                                           
  ----------------------------------------------------------------------- ------------------- ------------- --------- ------------- ------------- ---------
  Age at baseline, mean in years (SD)                                     61.3 (4.2)          63.5 (4.3)    \<0.001   62.0 (4.1)    63.0 (3.8)    0.03
  Age at CRC diagnosis, mean in years (SD)                                                                            71.2 (5.6)    71.3 (5.6)    0.81
  Gender (% male)                                                         1,318 (50)          41 (51)       0.88      1,047 (60)    32 (48)       0.05
  Genetic sum score, *n* (%)                                                                                                                      
  Tertile 1                                                               988 (37)            34 (42)                 557 (32)      18 (27)       
  Tertile 2                                                               991 (38)            34 (42)                 697 (40)      33 (49)       
  Tertile 3                                                               669 (25)            13 (16)       0.17      500 (28)      16 (24)       0.30
  IGF1 CA repeat[1](#ijc32365-note-0002){ref-type="fn"}, *n* (%)                                                                                  
  Non‐19/non‐19                                                           509 (19)            11 (14)                 341 (19)      11 (17)       
  19/non‐19                                                               684 (26)            24 (30)                 566 (32)      14 (21)       
  19/19                                                                   600 (23)            18 (22)       0.60      522 (30)      25 (37)       0.12
  BMI, mean kg/m^2^ ± SD                                                  25.0 (3.1)          25.6 (3.6)    0.14      25.0 (2.9)    25.6 (3.2)    0.09
  Pants/skirt size, *n* (%) equal or above median                         1,568 (59)          53 (65)       0.26      1,086 (62)    50 (75)       0.04
  Family history of CRC, *n* (%) yes                                      160 (6)             3 (4)         0.63      176 (10)      4 (6)         0.27
  Smoking Status, *n* (%)                                                                                                                         
  Never                                                                   917 (35)            35 (43)                 525 (30)      29 (43)       
  Ex‐smoker                                                               1,002 (38)          30 (37)                 769 (44)      28 (42)       
  Current smoker                                                          729 (27)            16 (20)       0.18      460 (26)      10 (15)       0.03
  Alcohol intake, *n* (%)                                                                                                                         
  0 g/day                                                                 610 (23)            23 (29)                 342 (20)      25 (37)       
  0.1--30 g/day                                                           1,801 (68)          48 (59)                 1,181 (67)    37 (55)       
  \>30 g/day                                                              237 (9)             10 (12)       0.24      231 (13)      5 (8)         0.001
  Dietary habits                                                                                                                                  
  Total meat, mean in g/day (SD)[2](#ijc32365-note-0003){ref-type="fn"}   113 (46)            120 (46)      0.40      115 (47)      122 (41)      0.10
  Vegetables, mean in g/day (SD)                                          381 (159)           384 (148)     0.86      376 (164)     412 (153)     0.03
  Fish, mean in g/day (SD)                                                13 (15)             13 (17)       0.81      12 (15)       13 (13)       0.48
  Sweets, mean in g/day (SD)[3](#ijc32365-note-0004){ref-type="fn"}       42 (26)             31 (27)       \<0.001   42 (26)       31 (25)       \<0.001
  Added sugar, mean in g/day (SD)                                         20 (27)             5 (17)        \<0.001   21 (28)       1 (4)         \<0.001
  Saturated fats, mean in g/day (SD)                                      33 (11)             31 (11)       0.13      34 (11)       36 (16)       0.17
  Fiber intake, mean in g/day (SD)                                        27 (8)              27 (8)        0.51      27 (8)        29 (9)        0.10
  Energy, mean in kcal/day (SD)                                           1,922 (505)         1,823 (456)   0.06      1,976 (495)   1,928 (588)   0.51
  Physical activity, *n* (%)                                                                                                                      
  ≤30 min/day                                                             512 (19)            21 (26)                 340 (19)      19 (20)       
  \>30--≤60 min/day                                                       860 (33)            26 (32)                 533 (31)      16 (24)       
  \>60--≤90 min/day                                                       566 (21)            12 (15)                 386 (22)      18 (27)       
  \>90 min/day                                                            710 (27)            22 (27)       0.34      495 (28)      14 (21)       0.14

Numbers of IGF1 19‐CA repeat in baseline and analyses do not match due to exclusion of missing on the genetic sum score variable.

Consists of the sum of pork, beef, poultry, game, and processed meat intakes.

Consists of the sum of intakes of sweet sandwich filling, cookies, cake, and candy.

Abbreviations: BMI, body mass index; CRC, colorectal cancer; SD standard deviation; T2DM, type 2 diabetes mellitus.

The GRS and T2DM {#ijc32365-sec-0008}
----------------

CRC risks were increased across combined categories of T2DM and GRS using non‐T2DM individuals in the lowest tertile of the GRS as reference (Table [2](#ijc32365-tbl-0002){ref-type="table"}). Individuals with T2DM in the lowest GRS tertile did not differ in CRC risk (HR = 1.00, 95% CI: 0.54--1.83) from those without T2DM in the lowest tertile. Non‐T2DM individuals in the middle and highest GRS tertiles were at a statistically significant increased CRC risk as compared to non‐T2DM individuals in the lowest GRS tertile (HR~non‐T2DM\ in\ middle\ GRS\ tertile\ *vs*.\ non‐T2DM\ in\ lowest\ GRS\ tertile~ = 1.23, 95% CI: 1.06--1.42 and HR~non‐T2DM\ in\ highest\ GRS\ tertile\ *vs*.\ non‐T2DM\ in\ lowest\ GRS\ tertile~ = 1.27, 95% CI: 1.09--1.49), as were T2DM individuals in the middle and highest GRS tertiles HR~T2DM\ in\ middle\ GRS\ tertile\ *vs*.\ non‐T2DM\ in\ lowest\ GRS\ tertile~ = 1.82, 95% CI: 1.09--3.05, and HR~T2DM\ in\ highest\ GRS\ tertile\ *vs*.\ non‐T2DM\ in\ lowest\ GRS\ tertile~ = 2.28, 95% CI: 1.11--4.66). Sex‐specific analyses showed similar results as the overall analysis, although most HRs were not statistically significant. Subsite‐specific analyses showed that the results seen for CRC overall were most pronounced for proximal colon cancer (HR~T2DM\ in\ highest\ GRS\ tertile\ *vs*.\ non‐T2DM\ in\ lowest\ GRS\ tertile~ = 3.92, 95% CI: 1.75--8.79), but less clear in relation to distal colon cancer and rectal cancer. Power was insufficient to investigate subsite‐specific CRC risks in men and women separately. Stratified analyses yielded results that were not statistically significant, except when considering proximal colon cancer as endpoint and comparing T2DM with non‐T2DM individuals within the highest GRS tertile (HR = 3.93, 95% CI: 1.63--9.48). Tests for multiplicative and additive interactions (RERI) were not statistically significant.

###### 

Multivariable‐adjusted hazard ratios for colorectal cancer overall and by sex and subsite for combined categories of type 2 diabetes mellitus and tertiles of genetic risk score based on SNPs in genes from the IGF pathway and for type 2 diabetics *vs*. nondiabetics within tertiles of this genetic risk score in the Netherlands Cohort Study after 16.3 years of follow‐up

                                                                       Type 2 diabetes mellitus                Type 2 diabetes mellitus                                                                                 
  --------------------------------------------------------------- ---- -------------------------- ----- ------ -------------------------- ----- ---- ------ -------------- ------ --------------- ------ -------------- ------
  *Colorectum*                                                    T1   14,242                     587   1      (reference)                415   19   1.00   (0.54--1.83)                          1.10   (0.59--2.07)   
  Genetic risk score[**2**](#ijc32365-note-0007){ref-type="fn"}   T2   14,176                     732   1.23   (1.06--1.42)               446   34   1.82   (1.09--3.05)                          1.44   (0.85--2.42)   
                                                                  T3   9,736                      517   1.27   (1.09--1.49)               183   18   2.28   (1.11--4.66)   1.01   (−0.46--4.28)   1.98   (0.93--4.19)   0.43
  *Colorectum men*                                                T1   6,821                      346   1      (reference)                238   8    0.60   (0.25--1.46)                          0.65   (0.26--1.62)   
  Genetic risk score                                              T2   6,951                      431   1.21   (0.99--1.47)               194   18   1.94   (0.92--4.09)                          1.50   (0.69--3.27)   
                                                                  T3   4,428                      316   1.41   (1.13--1.75)               66    9    2.06   (0.71--5.95)   1.05   (−1.08--4.97)   1.43   (0.47--4.36)   0.22
  *Colorectum women*                                              T1   7,421                      241   1      (reference)                177   11   1.79   (0.77--4.17)                          2.05   (0.86--4.92)   
  Genetic risk score                                              T2   7,225                      301   1.25   (1.00--1.55)               252   16   1.96   (0.94--4.07)                          1.61   (0.76--3.41)   
                                                                  T3   5,308                      201   1.15   (0.91--1.47)               118   9    2.14   (0.78--5.89)   0.19   (−3.04--5.80)   1.96   (0.66--5.77)   0.96
  *Proximal colon cancer*                                         T1   14,242                     207   1      (reference)                415   8    1.17   (0.52--2.65)                          1.35   (0.57--3.21)   
  Genetic risk score                                              T2   14,176                     243   1.15   (0.93--1.42)               446   14   2.09   (1.07--4.08)                          1.74   (0.88--3.43)   
                                                                  T3   9,736                      163   1.14   (0.90--1.44)               183   12   3.92   (1.75--8.79)   2.61   (−0.47--7.17)   3.93   (1.63--9.48)   0.18
  *Distal colon cancer*                                           T1   14,242                     190   1      (reference)                415   5    0.79   (0.30--2.13)                          0.78   (0.28--2.15)   
  Genetic risk score                                              T2   14,176                     236   1.22   (0.98--1.52)               446   8    1.42   (0.63--3.17)                          1.10   (0.48--2.50)   
                                                                  T3   9,736                      177   1.36   (1.08--1.72)               183   4    1.53   (0.48--4.90)   0.37   (−1.66--3.84)   1.13   (0.33--3.91)   0.83
  *Rectal cancer*                                                 T1   14,242                     132   1      (reference)                415   4    0.88   (0.29--2.62)                          0.95   (0.30--2.98)   
  Genetic risk score                                              T2   14,176                     167   1.24   (0.97--1.60)               446   7    1.72   (0.73--4.08)                          1.40   (0.58--3.35)   
                                                                  T3   9,736                      120   1.36   (1.03--1.78)               183   2    1.25   (0.27--5.92)   0.02   (−1.70--6.02)   0.92   (0.18--4.79)   0.78

Hazard ratios were adjusted for age (years), body mass index (kg/m^2^), pants/skirt size (below, or equal to or above median size), family history of colorectal cancer (yes/no), smoking status (never, ex, current), alcohol intake (0, 0.1--29, ≥30 g/day), intake in g/day of total meat, vegetables, fish, sweets, added sugar, saturated fats, and fiber, total energy intake (kcal/day) and nonoccupational physical activity (≤30, \>30, \>60 and \>90 min/day).

The range in tertiles of the (literature‐based) genetic risk score was 6--14, 15--18 and 19--29 risk alleles. The theoretical maximum was 36. The distribution of subcohort members across tertiles was 988 (37.3%), 991 (37.4%) and 669 (25.3%), respectively, in individuals without type 2 diabetes mellitus and 34 (42.0%), 34 (42.0%) and 13 (16.0%), respectively, in individuals with type 2 diabetes mellitus.

Abbreviations: CI, confidence interval; HR, hazard ratio; PY, person‐years at risk; RERI, relative excess risk due to interaction.

The *IGF1* 19‐CA repeat polymorphism and T2DM {#ijc32365-sec-0009}
---------------------------------------------

Table [3](#ijc32365-tbl-0003){ref-type="table"} shows the CRC risks associated with combined categories of T2DM and the *IGF1* 19‐CA repeat polymorphism. Using non‐T2DM individuals homozygous for the wild‐type 19‐CA repeat allele as reference showed that non‐T2DM individuals carrying one or two variant *IGF1* 19‐CA repeat alleles had (a borderline) statistically significantly decreased CRC risk (HR = 0.88, 95% CI: 0.75--1.04 and HR = 0.76, 95% CI: 0.63--0.91, respectively), whereas CRC risk was not significantly changed in individuals with T2DM homozygous for the wild‐type *IGF1* 19‐CA repeat allele or those carrying one or two variant alleles (HR = 1.44, 95% CI: 0.76--2.74; HR = 0.73, 95% CI: 0.37--1.44; and HR = 1.26, 95% CI: 0.53--2.96, respectively). Sex‐specific analyses showed similar results in women and nonsignificant results in men. Subsite‐specific analyses showed similar results as overall analyses. Stratified analyses showed no statistically significant associations between T2DM and CRC risk overall or by subsite, except when considering proximal colon cancer as endpoint and comparing T2DM with non‐T2DM individuals within those carrying two variant IGF1 19‐CA repeat alleles (HR = 3.09, 95% CI: 1.03--9.24). Multiplicative and additive interactions were not statistically significant.

###### 

Multivariable‐adjusted hazard ratios for colorectal cancer overall and by sex and subsite for combined categories of type 2 diabetes mellitus and the *IGF1* 19‐CA repeat polymorphism and for type 2 diabetics *vs*. non‐diabetics within categories of the *IGF1* 19‐CA repeat polymorphism in the Netherlands Cohort Study after 16.3 years of follow‐up

                                                                                 Type 2 diabetes mellitus                Type 2 diabetes mellitus                                                                                  
  ------------------------------------------------------------ ----------------- -------------------------- ----- ------ -------------------------- ----- ---- ------ -------------- ------- --------------- ------ -------------- ------
  *Colorectum*                                                 192/192           9,296                      620   1      (reference)                280   26   1.44   (0.76--2.74)                           1.44   (0.76--2.72)   
  *IGF1* 19‐CA repeat[2](#ijc32365-note-0010){ref-type="fn"}   192/non‐192       10,950                     659   0.88   (0.75--1.04)               304   16   0.73   (0.37--1.44)                           0.83   (0.42--1.65)   
                                                               Non‐192/non‐192   8,238                      389   0.76   (0.63--0.91)               153   12   1.26   (0.53--2.96)   0.05    (−1.73--1.84)   1.89   (0.75--4.75)   0.36
  *Colorectum men*                                             192/192           5,027                      371   1      (reference)                115   10   1.05   (0.38--2.89)                           1.01   (0.34--2.98)   
  *IGF1* 19‐CA repeat                                          192/non‐192       5,628                      389   0.90   (0.73--1.12)               184   8    0.57   (0.23--1.43)                           0.57   (0.23--1.45)   
                                                               Non‐192/non‐192   3,274                      234   0.98   (0.76--1.25)               48    5    1.57   (0.37--6.62)   0.54    (−2.57--18.4)   1.88   (0.39--8.94)   0.52
  *Colorectum women*                                           192/192           4,269                      249   1      (reference)                165   16   1.87   (0.83--4.18)                           1.96   (0.84--4.54)   
  *IGF1* 19‐CA repeat                                          192/non‐192       5,322                      270   0.85   0.83--1.08                 120   8    1.22   (0.44--3.42)                           1.07   (0.34--3.34)   
                                                               Non‐192/non‐192   4,964                      155   0.54   0.42--0.71                 105   7    1.21   (0.41--3.60)   −0.20   (−3.85--1.75)   2.35   (0.79--6.97)   0.85
  *Proximal colon cancer*                                      192/192           9,296                      218   1      (reference)                280   13   1.95   (0.91--4.16)                           1.97   (0.90--4.30)   
  *IGF1* 19‐CA repeat                                          192/non‐192       10,950                     229   0.86   (0.69--1.07)               304   9    1.21   (0.53--2.74)                           1.45   (0.63--3.34)   
                                                               Non‐192/non‐192   8,238                      123   0.64   (0.50--0.83)               153   6    1.63   (0.58--4.60)   0.04    (−3.00--3.07)   3.09   (1.03--9.24)   0.66
  *Distal colon cancer*                                        192/192           9,296                      215   1      (reference)                280   5    0.81   (0.29--2.27)                           0.77   (0.27--2.16)   
  *IGF1* 19‐CA repeat                                          192/non‐192       10,950                     209   0.82   (0.65--1.02)               304   3    0.41   (0.12--1.39)                           0.51   (0.15--1.74)   
                                                               Non‐192/non‐192   8,238                      131   0.76   (0.58--0.96)               153   4    1.32   (0.40--4.36)   0.76    (−1.27--2.79)   1.95   (0.54--7.07)   0.34
  *Rectal cancer*                                              192/192           9,296                      126   1      (reference)                280   5    1.44   (0.51--4.09)                           1.53   (0.54--4.37)   
  *IGF1* 19‐CA repeat[2](#ijc32365-note-0010){ref-type="fn"}   192/non‐192       10,950                     147   0.97   (0.74--1.27)               304   3    0.64   (0.18--2.25)                           0.65   (0.18--2.35)   
                                                               Non‐192/non‐192   8,238                      91    0.90   (0.66--1.22)               153   2    1.07   (0.23--5.04)   −0.28   (−2.65--2.10)   1.30   (0.27--6.35)   0.64

Hazard ratios were adjusted for age (years), body mass index (kg/m^2^), pants/skirt size (median split, Dutch sizes), family history of colorectal cancer (yes/no), smoking status (never, ex, current), alcohol intake (0, 0.1--29, ≥30 g/day), intake in g/day of total meat, vegetables, fish, sweets, added sugar, saturated fats and fiber, total energy intake (kcal/day) and nonoccupational physical activity (≤30, \>30, \>60 and \>90 min/day).

The distribution of subcohort members across categories of the *IGF1* 19‐CA repeat polymorphism was 567 (28.6%), 751 (37.8%) and 667 (33.6%), respectively, in individuals without type 2 diabetes mellitus and 13 (35.0%), 24 (42.0%) and 20 (23.0%), respectively, in individuals with type 2 diabetes mellitus.

Abbreviations: CI, confidence interval; HR, hazard ratio; RERI, relative excess risk due to interaction; PY, person‐years; IGF1, insulin‐like growth factor 1.

Discussion {#ijc32365-sec-0010}
==========

In this long‐term prospective study, we used genetic variation in the IGF pathway as time‐independent markers of IGF pathway involvement. To the best of our knowledge, our study is the first to simultaneously consider T2DM with markers of IGF pathway involvement in relation to CRC risk. Comparison of combined categories with non‐T2DM in the lowest GRS tertile as reference showed that the presence of more unfavorable alleles in the IGF pathway was associated with an increased CRC risk in both the presence and absence of T2DM, with strongly increased CRC risks observed in the presence of T2DM. These data suggest the main effect of the GRS and a possible joint effect of T2DM and the GRS. As compared to non‐T2DM wild‐type *IGF1* 19‐CA repeat carriers, carrying two *IGF1* 19‐CA variant repeat alleles was associated with a decreased CRC risk in the absence of T2DM, and this association was absent in the presence of T2DM. However, in all analyses, multiplicative and additive interactions were not statistically significant. We found no clear sex differences in any of the analyses performed. Subsite‐specific analyses in relation to proximal colon cancer risk were most similar to overall analyses.

The most recent meta‐analysis has shown T2DM to be a risk factor for CRC,[3](#ijc32365-bib-0003){ref-type="ref"} although the individual studies used, showed conflicting results regarding subsite‐ and sex‐specific CRC risks.[18](#ijc32365-bib-0018){ref-type="ref"}, [19](#ijc32365-bib-0019){ref-type="ref"} Using NLCS data,[6](#ijc32365-bib-0006){ref-type="ref"} we have previously reported T2DM to be associated with an increased proximal colon cancer risk in women. In the current study, findings should be interpreted with caution as the number of CRC cases with T2DM per CRC subsite was low. However, the finding that T2DM was a statistically significant risk factor for proximal colon cancer in the presence of an accumulation of risk alleles in the IGF pathway at least shows consistency with previous findings regarding the T2DM‐CRC association in the NLCS and other cohort studies.[7](#ijc32365-bib-0007){ref-type="ref"} Differences in embryological origin of subsites and consequently variations in susceptibility to influences of T2DM and IGF1 as a growth factor could theoretically explain why we observed associations with proximal colon cancer specifically.[20](#ijc32365-bib-0020){ref-type="ref"}

The absence of statistically significant interactions between T2DM and a GRS based on risk alleles in genes in the IGF pathway may be due to a lack of power resulting from the low prevalence of T2DM in our study and the absence of a (strong) main effect of T2DM on CRC risk overall in individuals in the lowest GRS tertile. A prior study by Simons *et al*.[21](#ijc32365-bib-0021){ref-type="ref"} within our research group showed that larger body size may be a CRC risk factor in men in the presence of an accumulation of unfavorable alleles in the IGF pathway. This previous study gives confidence in our present findings as both BMI and T2DM are independent CRC risk factors that both are thought to act through the IGF pathway.[22](#ijc32365-bib-0022){ref-type="ref"}

The analyses in which we simultaneously considered T2DM and the *IGF1* 19‐CA repeat polymorphism showed no risk pattern other than that *IGF1* 19‐CA variant repeat carriers as compared to wild‐type repeat carriers in the absence of T2DM were associated with a (borderline) statistically significantly lower CRC risk. Although there is some inconsistency in the literature regarding the direction of the association between the *IGF1* 19‐CA repeat polymorphism and CRC risk,[23](#ijc32365-bib-0023){ref-type="ref"} the *IGF1* 19‐CA wild‐type repeat status has been associated with higher IGF‐I serum levels[13](#ijc32365-bib-0013){ref-type="ref"} than a nonwild‐type repeat status, and higher IGF‐I serum levels have been associated with an increased CRC risk.[24](#ijc32365-bib-0024){ref-type="ref"} For comparison, in the study by Simons *et al*.,[21](#ijc32365-bib-0021){ref-type="ref"} a decreased CRC risk in women was found for *IGF1* 19‐CA variant *vs*. wild‐type repeat carriers regardless of BMI. Although this is not entirely consistent with the present findings, one could carefully speculate that the CRC protective effects of *IGF1* 19‐CA variant repeat alleles might be negated by a metabolically unhealthy state of prolonged exposure to IGFs and other growth factors, which may be captured by the presence of T2DM but not BMI, at least not in the NLCS. The NLCS includes relatively few individuals that reported to be obese (BMI \> 30 kg/m^2^) at baseline (9.6%), which is consistent with the relatively low prevalence of diabetes. T2DM, in this regard, as opposed to BMI, may have better or very specifically captured metabolically unhealthy individuals in our cohort.

Strengths of our study include the prospective design, limiting the chance of selection and information bias, the fact that we had information on many potential confounders, and a large number of CRC cases. In addition, the use of a GRS reduced the number of tests that had to be performed, minimizing the chance of false positive results due to multiple testing. However, the prevalence of T2DM in this cohort was low, limiting power. Another limitation of our study is that we had no repeated exposure measurements during the long follow‐up period. As such, HRs may have been underestimated, considering that it is likely that some of the nondiabetic individuals were diagnosed with T2DM after our baseline measurement, as the population grew older. These individuals will have been misclassified as nondiabetic individuals in the present study, resulting in a smaller exposure contrast between the groups. Furthermore, classification of T2DM was performed on the basis of self‐reports, which could have resulted in underdiagnosed T2DM in our cohort. However, previous studies within large cohorts have shown that the self‐report of treated diabetes is an accurate proxy to use in epidemiologic studies.[25](#ijc32365-bib-0025){ref-type="ref"}

To conclude, our study of joint effects indicated that the presence of unfavorable alleles in the IGF pathway may further increase the risk of CRC associated with T2DM. Genetic variation in the IGF pathway could prove useful in future studies assessing personalized CRC risk.
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